- Trials with a EudraCT protocol (1,551)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (7)
1,551 result(s) found for: CRP.
Displaying page 68 of 78.
EudraCT Number: 2007-005759-41 | Sponsor Protocol Number: WA20496 | Start Date*: 2008-03-19 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the safety and Efficacy of Ocrelizumab Given as a Single Infusion or Dual Infusion Compared with Placebo in Patients with... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Completed) DE (Prematurely Ended) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004331-39 | Sponsor Protocol Number: INDOOR | Start Date*: 2015-01-02 | |||||||||||
Sponsor Name:Fundació Vall Hebron Institut de Recerca | |||||||||||||
Full Title: HIV Reservoir Dynamics After Switching To Dolutegravir in Patients on a PI/r Based Regimen. A Phase IV Open Randomized Trial | |||||||||||||
Medical condition: HIV-1 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020423-51 | Sponsor Protocol Number: ETA0881X1-4718 | Start Date*: 2011-02-17 | |||||||||||
Sponsor Name:Asklepios Klinik Sankt Augustin | |||||||||||||
Full Title: Remission Induction by Etanercept in Enthesitis related Arthritis JIA-Patients (juvenile undifferentiated Spondylarthropathy) | |||||||||||||
Medical condition: Active enthesitis-related arthrtitis as a category of juvenile idiopathic arthritis (ERA-JIA) as determined by International League of Associations for Rheumatology (ILAR) criteria. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005288-86 | Sponsor Protocol Number: C87077 | Start Date*: 2009-03-18 | |||||||||||
Sponsor Name:UCB Pharma S.A. | |||||||||||||
Full Title: A Phase IIIb, open-label, run-in and double-blind, placebo-controlled, randomized study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with stable-dose methotr... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000515-15 | Sponsor Protocol Number: C LF0242780-01 05 04 | Start Date*: 2007-01-30 | |||||||||||
Sponsor Name:FOURNIER LABORATORIES IRELAND Ltd | |||||||||||||
Full Title: A multicenter, double-blind, randomized, forced-titration study to compare the efficacy and safety of the combination of 145 mg fenofibrate and 20 or 40 mg simvastatin with 40 mg pravastatin monoth... | |||||||||||||
Medical condition: Study in patients with mixed dyslipidemia at risk of cardiovascular disease not adequately controlled by 40 mg pravastatin alone. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005449-19 | Sponsor Protocol Number: | Start Date*: 2013-04-24 | |||||||||||
Sponsor Name:Hull and East Yorkshire Hospitals NHS Trust | |||||||||||||
Full Title: A double-blind, randomised controlled trial of percutaneous transluminal angioplasty (PTA) & Ramipril versus PTA & placebo in the management of intermittent claudication (IC) | |||||||||||||
Medical condition: Peripheral Arterial Disease: Intermittent Claudication | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002896-40 | Sponsor Protocol Number: B3281001 | Start Date*: 2012-08-14 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, STUDY COMPARING THE PHARMACOKINETICS AND PHARMACODYNAMICS, AND ASSESSING THE SAFETY OF PF-05280586 AND RITUXIMAB IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS ON A BACKGR... | |||||||||||||
Medical condition: RHEUMATOID ARTHRITIS | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) DE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004354-15 | Sponsor Protocol Number: DANPAPP | Start Date*: 2017-12-13 | ||||||||||||||||
Sponsor Name: Rigshospitalet | ||||||||||||||||||
Full Title: Prevalence, pattern and disease course of arthritis and enthesitis in patients with psoriasis, and the effect of apremilast in subclinical US-defined psoriatic arthritis - A population-based study ... | ||||||||||||||||||
Medical condition: Psoriasis and psoriatic arthritis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-020872-49 | Sponsor Protocol Number: PI10-Pr.CHOUKROUN-FRENCH | Start Date*: 2013-04-18 | |||||||||||
Sponsor Name:CHU Amiens | |||||||||||||
Full Title: Étude randomisée, en double aveugle, versus placebo, évaluant chez des patients porteurs d'une MRC, non dialysés, l'effet du traitement par carbonate de sevelamer sur le contrôle des taux sériques ... | |||||||||||||
Medical condition: Maladies Rénales Chroniques au stade 3b et 4 (DFG compris entre 15 et 45 ml/min) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004545-32 | Sponsor Protocol Number: EP-002 | Start Date*: 2020-04-16 | |||||||||||
Sponsor Name:Empros Pharma AB | |||||||||||||
Full Title: Lean Efficacy Phase IIa Proof of concept trial (LEAAP). A multi-centre, double-blind, placebo controlled, randomised study in overweight and obese patients during twenty-six weeks, investigating th... | |||||||||||||
Medical condition: Obesity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005370-62 | Sponsor Protocol Number: ANAKIN-RA-DIABETES | Start Date*: 2013-02-18 | ||||||||||||||||
Sponsor Name:OSPEDALE CIVILE SAN SALVATORE, ASL 04, L'AQUILA | ||||||||||||||||||
Full Title: “No-profit” clinical study for the improvement of clinical practice, to evaluate the efficacy of anakinra in reducing the glycated haemoglobin in patients affected by rheumatoid arthritis and diabe... | ||||||||||||||||||
Medical condition: rheumatoid arthritis and type 2 diabetes mellitus as comorbidity. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001748-24 | Sponsor Protocol Number: ImmCoVA | Start Date*: 2020-05-15 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treat... | ||
Medical condition: COVID-19 infection in patients with respiratory distress. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-000699-32 | Sponsor Protocol Number: EU-0208/REMICADEPSO1006 | Start Date*: 2011-09-28 | |||||||||||
Sponsor Name:UZ KULeuven, service of Rheumatology | |||||||||||||
Full Title: Nail involvement in psoriatic arthritis: a cross-sectional and observational prospective study. | |||||||||||||
Medical condition: psoriatic artritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000684-33 | Sponsor Protocol Number: OC5-DB-02 | Start Date*: 2017-06-06 | |||||||||||
Sponsor Name:OxThera Intellectual Property AB | |||||||||||||
Full Title: A phase III double-blind, randomized study to evaluate the long-term efficacy and safety of Oxabact® in patients with primary hyperoxaluria | |||||||||||||
Medical condition: Primary Hyperoxaluria (PH) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed) BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001880-22 | Sponsor Protocol Number: PP-CT02 | Start Date*: 2018-08-23 | |||||||||||
Sponsor Name:PILA PHARMA AB | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, parallel-group trial investigating the effect of 4 weeks bi-daily dosing of XEN-D0501 on blood glucose reduction as add-on to metformin in patients w... | |||||||||||||
Medical condition: Diabetes Type II | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002130-33 | Sponsor Protocol Number: ZILU-COV | Start Date*: 2020-05-26 |
Sponsor Name:University Hospital Ghent | ||
Full Title: A prospective, randomized, open-label, interventional study to investigate the efficacy of complement C5 inhibition with Zilucoplan® in improving oxygenation and short- and long-term outcome of COV... | ||
Medical condition: COVID-19 patients with acute hypoxic respiratory failure. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000598-95 | Sponsor Protocol Number: HS-20-674 | Start Date*: 2021-07-30 | |||||||||||
Sponsor Name:Camurus AB | |||||||||||||
Full Title: A Phase 2, randomized, double-blind, placebo-controlled, multi-center trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acute respiratory distress ... | |||||||||||||
Medical condition: Acute respiratory distress syndrome (ARDS) caused by COVID-19 or other disorders | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004826-27 | Sponsor Protocol Number: GI1863 | Start Date*: 2019-04-11 | |||||||||||||||||||||||||||||||
Sponsor Name:Department of Oncology, Herlev & Gentofte Hospital | |||||||||||||||||||||||||||||||||
Full Title: A Single Center, Randomized, Phase II Study of the combination of Cisplatin and Gemcitabine with or without Tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advance... | |||||||||||||||||||||||||||||||||
Medical condition: First-line treatment in patients with locally advanced or metastatic biliary tract cancer, inoperable due to extension of the disease. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002023-28 | Sponsor Protocol Number: N/2015/70 | Start Date*: 2018-06-04 | |||||||||||
Sponsor Name:CHU Besançon | |||||||||||||
Full Title: Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early post-transplant period | |||||||||||||
Medical condition: Transplanté rénal à haut risque de développer un diabète de novo | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002028-19 | Sponsor Protocol Number: RH-CARD-Pharma001 | Start Date*: 2022-02-01 | |||||||||||
Sponsor Name:Department of Cardiology, Copenhagen University Hospital Rigshospitalet | |||||||||||||
Full Title: Low-dose dobutamine infusion and single-dose tocilizumab in acute myocardial infarction patients with high risk of cardiogenic shock development – a 2x2 multifactorial, double-blinded, randomized, ... | |||||||||||||
Medical condition: Acute Myocardial Infarction with increased risk of Cardiogenic Shock. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
